Health Canada Clears Palisade Bio ASCENTRA-UC Trial
Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The Canada — Health Canada clearance is a modest positive milestone for Palisade Bio, expanding the ASCENTRA-UC trial into Canada and supporting enrollment timelines, but it does not change near-term revenue prospects given efficacy data is not expected until the second half of 2027. Market reaction was muted, with PALI shares trading down 2.96% at $1.64, reflecting limited immediate financial impact for a clinical-stage biopharmaceutical company.
Palisade Bio, Inc. (Nasdaq: PALI) announced that Canada — Health Canada has cleared its Clinical Trial Application (CTA) for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance enables Palisade to advance clinical trial activities in Canada, expanding the study's geographic reach and supporting planned enrollment, and follows prior regulatory clearance in the United States. ASCENTRA-UC is a global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase 2 trial expected to enroll approximately 204 patients, evaluating once-daily 15 mg and 30 mg doses of PALI-2108 against placebo. The primary endpoint is clinical remission at Week 12 measured by the modified Mayo Score, with key secondary endpoints including clinical response, endoscopic improvement and histologic-endoscopic mucosal improvement. The study also includes a 36-week maintenance phase extension to assess durability of response and longer-term safety through Week 48. Palisade Bio stated it remains on track to begin patient dosing in the second half of 2026, with primary efficacy results from the 12-week induction period expected in the second half of 2027. PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for targeted activation in the terminal ileum and colon. Palisade shares traded between $0.64 and $2.86 over the last year, and PALI was trading down 2.96% at $1.64 following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard